Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

This expansion positions Dupixent as the first targeted therapy for COPD ... Further boosting the pipeline, mid-stage drugs ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

SANOFI added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic oesophagitis (EoE) in young patients. The drug has been specifically authorised for ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...